CL2018000664A1 - Método in vitro para identificar una enfermedad relacionada con el embarazo - Google Patents

Método in vitro para identificar una enfermedad relacionada con el embarazo

Info

Publication number
CL2018000664A1
CL2018000664A1 CL2018000664A CL2018000664A CL2018000664A1 CL 2018000664 A1 CL2018000664 A1 CL 2018000664A1 CL 2018000664 A CL2018000664 A CL 2018000664A CL 2018000664 A CL2018000664 A CL 2018000664A CL 2018000664 A1 CL2018000664 A1 CL 2018000664A1
Authority
CL
Chile
Prior art keywords
pregnancy
identify
vitro method
effective
disease related
Prior art date
Application number
CL2018000664A
Other languages
English (en)
Inventor
Padilla Alejandra Chaparro
Lopez Sebastian Illanes
Original Assignee
Univ Los Andes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Los Andes filed Critical Univ Los Andes
Publication of CL2018000664A1 publication Critical patent/CL2018000664A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Método in vitro para identificar o examinar humanos en riesgo de enfermedad relacionada con el embarazo, en particular diabetes mellitus gestacional o preeclampsia, a partir de expresión de biomarcadores aislados de fluido crevicular gingival (FCG). El método tiene alta sensibilidad y especificidad en etapa temprana de embarazo, es eficaz y rentable para la detección de dichas enfermedades, procurando tratamiento eficaz y evitando efectos adversos significativos a largo plazo para madre y bebé.
CL2018000664A 2015-09-11 2018-03-12 Método in vitro para identificar una enfermedad relacionada con el embarazo CL2018000664A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562217270P 2015-09-11 2015-09-11
EP16161490 2016-03-21

Publications (1)

Publication Number Publication Date
CL2018000664A1 true CL2018000664A1 (es) 2019-02-08

Family

ID=65588794

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000664A CL2018000664A1 (es) 2015-09-11 2018-03-12 Método in vitro para identificar una enfermedad relacionada con el embarazo

Country Status (2)

Country Link
US (1) US11035864B2 (es)
CL (1) CL2018000664A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005017192A2 (en) 2003-08-14 2005-02-24 The General Hospital Corporation Screening for gestational disorders
WO2006069373A2 (en) 2004-12-21 2006-06-29 Yale University Diagnosis of preeclampsia
US20070218519A1 (en) 2005-10-11 2007-09-20 Tethys Bioscience, Inc. Diabetes-associated markers and methods of use thereof
WO2014142752A1 (en) 2013-03-12 2014-09-18 Agency For Science, Technology And Research Pre-eclampsia biomarkers

Also Published As

Publication number Publication date
US20190331691A1 (en) 2019-10-31
US11035864B2 (en) 2021-06-15

Similar Documents

Publication Publication Date Title
BR112018010933A2 (pt) anticorpos multiespecíficos
CO2017013272A2 (es) Arquitectura basada en bloques con ejecución paralela de bloques sucesivos
ES2656150T3 (es) Diagnóstico de la sepsis y del síndrome de respuesta inflamatoria sistémica
WO2015176066A3 (en) Lpa-associated protein and rna expression
FR3021970B1 (fr) Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
CO2020004831A2 (es) Dosis y administración de anticuerpos antic-c5 para el tratamiento de pacientes con glomerulonefritis membranoproliferativa
BR112013007457A8 (pt) Formulações farmacêuticas contendo rifaximina, processos para a sua obtenção e método de tratar doença intestinal
ITUB20161187A1 (it) Sistema e procedimento per l’associazione dei risultati di analisi eseguite su campioni biologici, in particolare campioni biologici sottoposti ad indagini cliniche, con variabili pre-analitiche a cui detti campioni sono esposti.
BR112016018205A8 (pt) métodos de tratamento de mal de alzheimer, de seleção de pacientes, de identificação de pacientes, de previsão, de otimização da eficácia terapêutica, kit, uso de agente e uso in vitro de agente
BR112016004297A2 (pt) método para o tratamento de doença fibrótica
CL2012002560A1 (es) Metodos para el tratamiento de ulceras de pie diabetico que comprende un peptido de al menos 5 aminoacidos contiguos de nle3 a(1-7) efectivo; formulacion farmacéutica que comprende hidroxietil celulosa (hec) y un peptido de al menos 5 aminoacidos contiguos de nle3 a(1-7).
BR112016009460A8 (pt) método para detectar a presença de anticorpos neutralizantes, e, kit
CO2017013275A2 (es) Índice de búsqueda personal con privacidad mejorada"
WO2014139885A3 (en) Molecular targets and inhibitors of said targets, useful in the treatment of diseases associated with epithelial mesenchymal transition
BR112015000685A2 (pt) método para a identificação de risco clínico em um paciente possuindo ou suspeito de possuir uma infecção por influenza, método para a identificação de influenza ou pneumonia viral em um paciente, kit, método para avaliar a eficácia de um agente para o tratamento de influenza e para reduzir a severidade da doença em um indivíduo exposto a um vírus influenza.
CL2013002006A1 (es) Composicion farmaceutica que comprende un anticuerpo aislado que se une especificamente al factor de celulas madres; metodo de produccion del anticuerpo; y su uso para tratar o prevenir una enfermedad de remodelacion tisular o fibrotica en un sujeto.
BR112016003129A2 (pt) método para detectar infecção por h.pylori
CL2017000578A1 (es) Tratamiento del cáncer con el inhibidor de la alfa-amilasa en los animales de compañia
AR092423A1 (es) Metodo de diagnostico y tratamiento del cancer dirigido a las moleculas expresadas en celulas madre cancerosas
BR112015027249A2 (pt) método de diagnóstico de câncer
WO2014107718A3 (en) Heat shock protein (hsp) inhibition and monitoring effectiveness thereof
CL2018000664A1 (es) Método in vitro para identificar una enfermedad relacionada con el embarazo
WO2018071504A3 (en) Methods of treating diseases with il-23a antibody
CO2019002599A2 (es) Biomarcadores proteicos para enfermedades asociadas con el sistema de activación por contacto
DOP2012000316A (es) Metodo para diagnosticar una respuesta al tratamiento en sujetos con esclerosis multiple